PE anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
RMP1-30 (See other available formats)
Regulatory Status
RUO
Other Names
Programmed Death-1, CD279, PDCD1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RMP1-30
Con A (3-day) activated C57BL/6 mouse splenocytes stained with RMP1-30 PE
  • RMP1-30
    Con A (3-day) activated C57BL/6 mouse splenocytes stained with RMP1-30 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
109103 50 µg 98€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
109104 200 µg 283€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279 is a 50-55 kD immunoglobulin superfamily member also known as programmed death-1 (PD-1). PD-1 is expressed on a subset of CD4-CD8- thymocytes and on activated T and B cells. PD-1 is thought to be involved in lymphocyte clonal selection and peripheral tolerance. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse PD-1 transfected BHK cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RMP1-30 antibody does not block the binding of PD-1 to B7-H1 and B7-DC1.

Application References
  1. Matsumoto K, et al. 2004. J. Immunol. 172:2530.
  2. Raimondi G, et al. 2006. J. Immunol. 176:2808. (FC) PubMed
  3. King IL, et al. 2009. J. Exp Med 206:1001. (FC) PubMed
Product Citations
  1. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  2. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  3. Vick SC, et al. 2021. J Immunol. 207:2598. PubMed
  4. Ozga AJ, et al. 2022. Immunity. 55:82. PubMed
  5. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  8. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  9. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  10. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  11. van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed
  12. Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed
  13. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  14. Bally AP, et al. 2017. J Immunol. 198:205. PubMed
  15. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  16. Barrow AD et al. 2018. Cell. 172(3):534-548 . PubMed
  17. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  18. Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed
  19. Bally A, et al. 2015. J Immunol. 194:4545. PubMed
  20. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  21. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  22. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  23. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  24. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  25. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  26. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  27. An J, et al. 2022. iScience. 25:103570. PubMed
  28. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  29. Zeng W, et al. 2016. Sci Rep. 6:36560. PubMed
  30. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  31. Karnowski A, et al. 2012. J Exp Med. 209:2049. PubMed
  32. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  33. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  34. Park S, et al. 2014. J Leukoc Biol. 95:621. PubMed
  35. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  36. Li H, et al. 2020. Nature. 584:274. PubMed
  37. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  38. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  39. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  40. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  41. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  42. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  43. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  44. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  45. Puleston D, et al. 2014. Elife. 3:3706. PubMed
  46. Park H, et al. 2012. Cell Immunol. 278:76. PubMed
RRID
AB_313420 (BioLegend Cat. No. 109103)
AB_313420 (BioLegend Cat. No. 109104)

Antigen Details

Structure
Ig superfamily, 50-55 kD
Distribution

Subset of double negative thymocytes, activated T and B cells

Function
Lymphocyte clonal selection, peripheral tolerance
Ligand/Receptor
PD-L1 (B7-H1), PD-L2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cancer Biomarkers, Cell Biology, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Agata Y, et al. 1996. Int. Immunol. 8:765.
3. Nishimura H, et al. 2001. Science 291:319.
4. Ishida Y, et al. 1992. EMBO J. 11:3887.

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account